An NCE is a type of chemical compound that has not been previously reported in scientific literature. It is a newly discovered chemical entity that has not been studied or characterized before. The discovery of NCEs is an important part of drug discovery research, as these compounds have the potential to be developed into new drugs for treating various diseases and medical conditions. Pharmaceutical companies invest significant time and resources into identifying and developing NCEs, with the ultimate goal of bringing new and effective treatments to patients. NCEs can come from a variety of sources, including natural products, synthetic chemistry, and biotechnology, and must go through extensive testing and regulatory approval processes before they can be brought to market.
In Europe, if a medicine contains a new chemical entity (NCE), the company can submit an application to the European Medicines Agency (EMA) for a Marketing Authorisation using the Centralised Procedure. Alternatively, they can submit an application to an individual Member State's regulatory authority, such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA). If the medicine has already been authorised in another Member State, the company can use the Mutual Recognition Procedure to apply for authorisation in additional countries.
New Chemical Entities (NCEs) can receive exclusivity from the FDA, which gives the company holding the approved drug application a limited protection period from new competition. It is crucial for those involved in the development of a new medicine to recognize the significance of regulatory affairs support and advice. By addressing regulatory strategy at an early stage, companies can increase their chances of bringing their product to the market efficiently and minimize the risk of being overtaken by competitors. This emphasizes the need for companies to seek professional guidance to ensure that they comply with regulatory requirements, meet necessary standards, and achieve successful market entry.
New Drugs, SND, FDC, API, Bulk Drugs, Test Licenses, BE NOC, etc. for importers, manufacturers and traders
Regulatory support for FSSAI. Import assistance, Licensing and registration, FSSAI compliance, Product Approval
Medical device registration, Import license, Clarification from CDSCO, Performance evaluation
Registration of biologicals, Import license, Test license, Export NOC, Regulatory support for CLAA
Registration of biologicals, Import license, Test license, Export NOC, Regulatory support for CLAA
Registration of biologicals, Import license, Test license, Export NOC, Regulatory support for CLAA
R.P/C.P
The medicines need to be handled with by a specialist, and for that matter, there is a requirement of a qualified pharmacist in case of retail drug license and in case of wholesale a graduate with 1 years experience or undergraduate having four years experience is must or any Diploma or Bachelor degree in Pharmacy.
Area For Drug Licence
For opening a pharmacy business, the carpet area of the pharmacy must be a minimum of 10 square meters, and in case the application is for both retail and wholesale pharmacy the minimum area prescribed in 15 square meters. The premises must be commercial and adequately ventilated.
I had been struggling to navigate the complex and ever-changing landscape of Indian regulatory services for years, until I found a reliable partner in Barrolex Consultants. Their team of experts not only helped me understand the intricacies of various regulations, but also provided invaluable.
I recently purchased a Miscellaneous product from this company and was blown away by the quality and attention to detail. The product exceeded my expectations and has been an essential part of my daily routine ever since.
cannot recommend Global Regulatory Services enough. Their team of experts provided us with invaluable guidance and support as we navigated the complex and ever-changing regulatory landscape. Thanks to their expertise,
Proactively revolutionize granular customer service after pandemic internal or "organic" sources. Distinctively impact proactive human capital rather than client-centered benefits.
Professionally impact distributed data via value-added experiences. Proacti incentivize 24/365 applications whereas turnkey total linkage. whiteboard multifunctional channels with interoperable value.
Professionally impact distributed data via value-added experiences. Proacti incentivize 24/365 applications whereas turnkey total linkage. whiteboard multifunctional channels with interoperable value.
Professionally impact distributed data via value-added experiences. Proacti incentivize 24/365 applications whereas turnkey total linkage. whiteboard multifunctional channels with interoperable value.
Professionally impact distributed data via value-added experiences. Proacti incentivize 24/365 applications whereas turnkey total linkage. whiteboard multifunctional channels with interoperable value.
Professionally impact distributed data via value-added experiences. Proacti incentivize 24/365 applications whereas turnkey total linkage. whiteboard multifunctional channels with interoperable value.
Professionally impact distributed data via value-added experiences. Proacti incentivize 24/365 applications whereas turnkey total linkage. whiteboard multifunctional channels with interoperable value.
